CD146 as an adverse prognostic factor in uterine sarcoma.
CD146 as an adverse prognostic factor in uterine sarcoma.
复制标题
CD146作为子宫肉瘤的不良预后因素
DOI：
10.1186/s40001-015-0160-2
复制
发表时间：
2015-08-21
影响因子：
4.2
通讯作者：
Zheng M
中科院分区：
文献类型：
--
作者：
Zhou Y;Huang H;Yuan LJ;Xiong Y;Huang X;Lin JX;Zheng M
背景子宫肉瘤是一种侵袭性强、预后差的恶性肿瘤。本研究旨在探讨CD 146、P53和Ki-67在子宫肉瘤中的表达及其与预后的关系。CD 146，P53，Ki-67的免疫组化分析进行了收集这些患者的组织样本和他们的关系与预后investigated.ResultsThe 5年总生存率（OS）为46%。子宫内膜间质肉瘤（ESS）患者的预后优于平滑肌肉瘤（LMS）患者，2年生存率为82%。ESS组中8例（32%）肿瘤细胞胞膜和胞浆CD 146阳性表达，低于LMS组25例（69.4%）和MMMT组2例（28.6%）。CD 146在子宫肉瘤细胞膜和胞浆中的表达与淋巴结转移（P= 0.021）和Ki-67的表达（P= 0.0053）密切相关，而与年龄、肿瘤大小、国际妇产科联合会分期及P53在子宫肉瘤中的表达无明显相关性。CD 146表达与淋巴结转移相关，并与LMS的OS差相关;它可能是LMS的潜在预后标志物。
BackgroundUterine sarcoma is an aggressive malignancy with a poor prognosis. This study aimed to determine the expression of CD146, P53, and Ki-67 in uterine sarcoma and to evaluate their prognostic significance.MethodsWe retrospectively analyzed the prognosis and clinicopathologic features of 68 patients with uterine sarcoma. Immunohistochemical analyses of CD146, P53, and Ki-67 were performed in tissue samples collected from these patients and their relationship with prognosis was investigated.ResultsThe 5-year overall survival (OS) rate was 46 %. Endometrial stromal sarcoma (ESS) patients had a better prognosis than leiomyosarcoma (LMS) patients, with a 2-year survival rate of 82 %. The membrane and cytoplasm of tumor cells exhibited CD146 overexpression in 8 (32 %) ESS cases, which was less than the 25 (69.4 %) cases observed in LMS and 2 (28.6 %) in MMMT. CD146 overexpression in the membrane and cytoplasm of tumor cells was closely related to lymph node metastasis (P= 0.021) and Ki-67 overexpression (P= 0.0053); there was no significant correlation with age, tumor size, International Federation of Obstetrics and Gynecology stage, or P53 overexpression in LMS.ConclusionsCD146, P53, and Ki-67 are overexpressed in uterine sarcoma. CD146 expression correlates with lymph node metastasis and is associated with poor OS in LMS; it may be a potential prognostic marker for LMS.